Plain-English translation of NCT07288398 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called levosimendag to see if it can help people who have high blood pressure in their lungs combined with a specific type of heart failure. Researchers want to know if this treatment can improve how far people can walk and reduce their symptoms. About 540 people will participate, with two-thirds receiving the medication and one-third receiving a placebo (a dummy pill).
High blood pressure in the lungs caused by heart failure is a serious condition that limits how much physical activity people can do. Doctors need better treatment options, and this medication may help by improving how the heart pumps blood and reducing strain on the lungs.
You likely qualify if…
You likely don't qualify if…
You would take a daily oral pill (either the medication or placebo) and visit the clinic regularly for heart exams, blood tests, and exercise tests to measure how far you can walk. The main study lasts several months, and if you're interested, you can continue in an additional 52-week extension phase where everyone receives the active medication. Throughout, doctors will monitor your heart health closely to see if the treatment is helping your symptoms.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States